More on: Vitamin K antagonists and cancer

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 8, 2008, Pages 1442-1443

  Schulman, Sam ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HHS General Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; WARFARIN;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER INCIDENCE; CANCER SURVIVAL; DISEASE ASSOCIATION; HUMAN; LETTER; NEOPLASM; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION; UROGENITAL TRACT CANCER; VENOUS THROMBOEMBOLISM;

EID: 47649116733     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03045.x     Document Type: Letter

References (8)

1. Schulman S, Lindmarker P. Incidence of cancer after secondary prophylaxis against venous thromboembolism with warfarin. N Engl J Med 2000; 342: 1953-8.
2. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345: 165-9.
3. Taliani MR, Agnelli G, Prandoni P, Becattini C, Moia M, Bazzan M, Ageno W, Tomasi C, Guazzaloca G, Ambrosio GB, Bertoldi A, Salvi R, Poggio R, Silingardi M. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. Warfarin Optimal Duration Italian Trial (WODIT) Investigators. J Thromb Haemost 2003; 1: 1730-3.
4. Prandoni P, Lensing AW, Büller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-33.
5. Tagalakis V, Tamim H, Blostein M, Collet JP, Hanley JA, Kahn SR. Use of warfarin and risk of urogenital cancer: A population-based, nested case-control study. Lancet Oncol 2007; 8: 395-402.
6. Blumentals WA, Foulis PR, Schwartz SW, Mason TJ. Does warfarin therapy influence the risk of bladder cancer? Thromb Haemost 2004; 91: 801-5.
7. Carpi A, Sagripanti A, Poddighe R, Gherarducci G, Nicolini A. Cancer incidence and mortality in patients with heart disease. Effect of oral anticoagulant therapy. Am J Clin Oncol 1995; 18: 15-8.
8. Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR. The effect of anticoagulants on cancer risk and survival: Systematic review. Cancer Treat Rev 2007; 33: 358-68.